Loading clinical trials...
Loading clinical trials...
The Effect of Magnesium Sulfate in Comparison to Clonidine as Adjuvants to Bupivacaine 0.25% in Supraclavicular Brachial Plexus Block in Pediatric Upper Limb Surgeries. Prospective, Randomized, Double-blind Study
Among paediatrics aging 3:12 who are going to have upper limb surgery,does adding clonidine to bupivacaine improve brachial plexus block outcome in comparison with magnesium sulfate with bupivacaine?
In upper extremity surgery, brachial plexus blocks are often preferred due to their advantages, such as long postoperative analgesic efficacy and shortening the length of hospital stay. This application reduces the use of opioids for postoperative analgesia and provides protection from their side effects. However, procedure failure, nerve injury and intravascular injection are the most common complications in the past years. In recent years, performing ultrasound-guided blocks has increased the success of the procedure and decreased the complication rate. Low number of studies, knowledge and experience in paediatric patients led to worries that complications will be more common and caused less use of regional techniques. However, good visualization of the anatomy in ultrasound-guided blocks and successful results in adult patients brought up the application of ultrasound-guided brachial plexus blocks in children. Effective postoperative analgesia improves patient's outcome in terms of early ambulation, decreased complications, and reduced incidence of postoperative chronic pain. Regional anaesthetics is a safe and effective method for upper limb surgeries. This method can prolong analgesia and reduce postoperative pain. Nowadays, peripheral nerve block has found an important role in anaesthesiology. Safety and high success rate have made it a common technique in outpatient and inpatient anaesthetics. Upper limb surgeries are mostly performed under peripheral nerve blocks such as brachial plexus block. Brachial plexus may be blocked in the level above the clavicle as interscalene and supraclavicular blocks or below the clavicle as infraclavicular and axillary blocks. Supraclavicular brachial plexus block is used for surgeries of the upper limb below the arm, from elbow to hand. Brachial plexus is blocked in the level between trunks and divisions. In this level, a small volume of local anaesthetic is needed for reliable block. The guide of ultrasound allows the anaesthesiologist to see the subclavian artery as a bold marker and neural structures around it above the 1st rib Regional anaesthetics may be one of the best solutions for intraoperative and postoperative paediatric pain management; Supraclavicular brachial plexus block is considered as one of the most effective anaesthetic methods for upper extremity surgeries. Its major drawback, especially in children, is the risk of pneumothorax, vascular puncture, and failure of the procedure due to inaccurate placement of the needle. Ultrasound-guided needle placement may reduce the risk of complications and increase the accuracy of block, particularly in paediatric patients. According to the surgeon's preference and due to the need for a tourniquet at the proximal part of the humerus in all surgeries regardless of the type of surgery, we considered supraclavicular block to be more suitable than more distal ones. This block can be done with only one injection around the plexus and provides sufficient anaesthetics at the tourniquet site as well. Lignocaine and bupivacaine are the commonly used local anaesthetics in Brachial plexus blocks. Lidocaine is an aminoamide, moderate acting local anaesthetic that blocks the peripheral afferents acting on voltage-dependent sodium channels, Bupivacaine is a potent local anaesthetic with unique characteristics from the amide group of local anaesthetics, which was first discovered in 1957 and widely used for prolonged local and regional anaesthetics. To increase the duration of local anaesthetic effect in the supraclavicular block,Local anaesthetics provide good anaesthetics in regional blocks, but have shorter duration of postoperative analgesia. Thereby, various adjuncts like opioids, clonidine, neostigmine, dexamethasone, alpha-2 agonists, dexmedetomidine, ketorolac, ketamine, and low-level laser therapy, have been used in regional blocks to achieve desirable analgesia. In the meantime, epinephrine is mostly used. Although epinephrine reduces the absorption of local anaesthetics, reduces their toxicity, and prolongs anaesthetic duration, it can cause hypertension and tachycardia. Therefore, its usage is limited when the patients have cardiovascular disease or hyperthyroidism Magnesium sulphate is an N-methyl D-aspartate (NMDA) receptor antagonist in the central nervous system (CNS) and peripheral nervous system (PNS). The NMDA receptor complex contains binding sites for antagonists such as magnesium. Magnesium is used as an adjuvant in peripheral nerve block. Anti-nociceptive effects of magnesium are due to the regulation of calcium influx into the cell and antagonism of the NMDA receptors. Many clinical studies have demonstrated that magnesium used during general anaesthetics reduced anaesthetic requirement and postoperative rescue analgesic. Magnesium has been commonly used as an antihypertensive agent. Magnesium may prevent postoperative shivering. More recently, it has been shown that magnesium sulfate decreased the effects of aminoamide local anaesthetics on rat sciatic nerves in vivo. Recently, alpha-2 receptor-stimulating drugs due to excellent sedative effects, analgesia, and anaesthetics with hemodynamic stability have been considered These pharmacologic properties have been employed clinically to achieve the desired effects in regional anaesthetics. Clonidine, an a2 adrenergic agonist has sedative, analgesic, perioperative sympatholytic with cardiovascular stabilizing effects and has been tried in combination with local anaesthetic drugs to enhance regional anaesthetics.
Age
3 - 12 years
Sex
ALL
Healthy Volunteers
No
Start Date
December 1, 2023
Primary Completion Date
June 1, 2024
Completion Date
July 1, 2024
Last Updated
December 26, 2023
70
ESTIMATED participants
magnesium sulfate.
DRUG
clonidine.
DRUG
Lead Sponsor
Assiut University
NCT06428461
NCT03528018
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions